A Case of Hand-Foot Skin Reaction-like Eruption Associated with Pembrolizumab

Main Article Content

Jade Young
Anna Eversman
Dina Poplausky
Yamato Suemitsu
George Niedt
Matthew Galsky
Joseph Sparano
Nicholas Gulati


hand food skin reaction, HFSR, cutaneous immune-related adverse event, cirae, immunotherapy, immune-checkpoint inhibitor, ICI, pembrolizumab, oncodermatology


1. Said JT, Singer S, Iannattone L, Sauder M, LeBoeuf NR. Outcomes of Acitretin Treatment for Refractory Multikinase Inhibitor–Induced Hand-Foot Skin Reaction. JAMA Dermatol. 2022;158(7):824-826. doi:10.1001/jamadermatol.2022.1425

2. Tan S, Day D, Nicholls SJ, Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(5):579-597. doi:10.1016/j.jaccao.2022.09.004

3. Yang C, Lin W, Chuang C, et al. Hand‐foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. British Journal of Dermatology. 2008;158(3):592-596. doi:10.1111/j.1365-2133.2007.08357.x

4. Chanprapaph K, Rutnin S, Vachiramon V. Multikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management. Am J Clin Dermatol. 2016;17(4):387-402. doi:10.1007/s40257-016-0197-1

5. Anderson RT, Keating KN, Doll HA, Camacho F. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. Oncologist. 2015;20(7):831-838. doi:10.1634/theoncologist.2014-0219